Ispire Technology Inc.
Ispire Technology Inc. (ISPR) Stock News
The latest ISPR headlines and market coverage — 10 recent stories, updated throughout the day.
- The Motley Fool·
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.
- The Motley Fool·
Why CRISPR Therapeutics Stock Rocked the Market Last Month
CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.
- The Motley Fool·
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.
- The Motley Fool·
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.
- GlobeNewswire Inc.·
Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth
The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.
- The Motley Fool·
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
CRISPR Therapeutics trades at a significant discount despite Wall Street analysts rating 58% as buy with 437% upside potential. The company's first commercialized product, Casgevy, treats sickle cell disease and beta thalassemia. With only 64 patients treated in 2025 and $4.1M in sales, analysts project revenue growth to $43.9M in 2026 and $151.6M in 2027. A strong pipeline of five additional therapies in clinical trials and a large addressable market of 60,000 eligible patients position CRISPR as a potential long-term growth opportunity, though highly speculative.
- The Motley Fool·
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
CRISPR Therapeutics acquired CTX611, a clinical-stage siRNA therapy targeting Factor XI for blood clot prevention, for $95 million upfront. The program could significantly impact the company's revenue despite being a follower in a competitive anticoagulant market dominated by Eliquis and other therapies. With only $1.4 million in Q1 2026 revenue, success with CTX611 could be transformative for the stock.
- The Motley Fool·
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has FDA-approved CASGEVY therapy and stronger financials, versus Editas Medicine, which focuses on in vivo gene editing but lacks FDA approval and has a weaker balance sheet. CRISPR Therapeutics is recommended as the better 2026 investment due to its commercial-stage advantage, stronger cash position, and lower financial risk, despite Editas offering potentially greater upside if successful.
- The Motley Fool·
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has an approved product (Casgevy) and a deeper pipeline, versus Beam Therapeutics, a clinical-stage company with a potentially safer base-editing platform. CRISPR Therapeutics is recommended as the better investment due to its approved product, stronger cash position ($2.4B vs $1.2B), and deeper pipeline, making it less risky despite both stocks carrying clinical trial risks.
- The Motley Fool·
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
CRISPR Therapeutics has bullish analyst sentiment with Piper Sandler's Edward Tenthoff setting a $110 price target, implying over 100% upside. The biotech's prospects are supported by upcoming clinical trial data for CTX611 (an anticoagulant targeting a $20B market), expansion of its approved Casgevy gene therapy to children, and a deep pipeline. However, the stock remains risky due to dependence on positive clinical results and execution.